Clinical Trial News and Research

RSS

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

Furiex reports financial and operating results for third quarter 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

6 Nov 2013

Depomed reports financial results for third quarter 2013

Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.

6 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that it has received approval to conduct a Phase IIb clinical trial for ReJoin, a human adipose-derived mesenchymal precursor cells (haMPC) therapy bio-engineered for Knee Osteoarthritis.

5 Nov 2013

Weight loss surgery: The most effective weapon for obese people in the battle against diabetes

Noted bariatric surgeon Michael Feiz, M.D., F.A.C.S., believes that there's no time like American Diabetes Month to point out that weight loss surgery is the most effective weapon obese people have in the battle against diabetes.

5 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Boehringer Ingelheim today announced new data from its Phase III clinical trial programme, STARTVerso, which evaluates faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV).

5 Nov 2013

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announced today top-line results from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.

5 Nov 2013

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute.

4 Nov 2013

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir, deleobuvir, PPI-668 and ribavirin.

4 Nov 2013

Polyphor, Roche agree to develop and commercialize antibiotic for bacterial infections

Polyphor Ltd, a privately held pharmaceutical company, and Roche announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor's investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa.

4 Nov 2013

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Women vaccinated with one dose of a human papillomavirus (HPV) vaccine had antibodies against the viruses that remained stable in their blood for four years, suggesting that a single dose of vaccine may be sufficient to generate long-term immune responses and protection against new HPV infections, and ultimately cervical cancer, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

4 Nov 2013

Current percutaneous techniques shed light on treatment of heart valve leakage

A Paravalvular regurgitation, or leakage, commonly affects valvular prostheses, particularly artificial valves placed percutaneously according to data presented at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) conference.

4 Nov 2013

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.

1 Nov 2013

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Crown serves pharmaceutical companies and biotech companies. We have two areas of focus: oncology and metabolic diseases. In the oncology space we focus on pre-clinical services. Essentially, we have all the tools to help our customers move from target discovery, target validation, to a clinical candidate.

31 Oct 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Protego develops sternal device for cardiac surgery with start-up investment from MRCF

Protego Medical Pty Ltd, an early stage medical technology company developing a medical device for sternal protection during cardiac surgery, was launched today with AU$2M start-up financing from Australia’s Medical Research Commercialisation Fund (MRCF). At the same time, the Company announced the appointment of Pablo Solis as CEO.

31 Oct 2013

Prestigious Janssen Industry Excellence Awards announced

The prestigious Janssen Industry Excellence Awards were announced as part of the official opening reception for the AusBiotech 2013 Conference at Brisbane City Hall last night; among them, internationally-acclaimed Brisbane-based researcher, Professor Ian Frazer.

31 Oct 2013

Clinical Trial News and Research

New treatment option for patients with most difficult-to-treat forms of hepatitis C

Furiex reports financial and operating results for third quarter 2013

Depomed reports financial results for third quarter 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Cellular Biomedicine Group gets approval to conduct ReJoin Phase IIb trial for Knee Osteoarthritis

Weight loss surgery: The most effective weapon for obese people in the battle against diabetes

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Pivotal Phase III STARTVerso data shows efficacy of faldaprevir in genotype-1 infected HCV patients

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Polyphor, Roche agree to develop and commercialize antibiotic for bacterial infections

Study: Single dose of HPV vaccine may be sufficient to protect cervical cancer

Current percutaneous techniques shed light on treatment of heart valve leakage

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Protego develops sternal device for cardiac surgery with start-up investment from MRCF

Prestigious Janssen Industry Excellence Awards announced

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer